References: Anticoagulation should be continued 3-6 months for the treatment of VTE in cancer patients: 1. ASCO: Lyman GH, Bohlke K, Khorana AA, et al.

Slides:

Advertisements

Similar presentations

Febrile Neutropenia Allison Ferrara, MD Princeton Baptist Medical Center Baptist Health Systems Alabama.

Advertisements

The Art of Medical Prophylaxis, Impacting the Patient Early Anna Falanga, MD Hemostasis and Thrombosis Center Hematology-Oncology Dept Ospedali Riuniti.

Supervisor: Vs 余垣斌 Presenter: CR 周益聖. INTRODUCTION.

Slides last updated: June 2015 CRC: CLINICAL FEATURES.

Surgical Care Improvement Project Prevention of Post-operative Venous Thromboembolism Team Membership Department of Surgery, Nursing, General Medicine,

Complicanze trombotiche nel mieloma multiplo Mauro Berrettini S.C. Medicina Generale-DH Oncologico Ospedale di Orvieto Mediterranean School of Oncology.

Pulmonary Embolism Treatment in Cancer - Is It Different 34th Brazilian Thoracic Conference 6th ALAT Congress 5th Brazil-Portugal Congress Brazilia/DF.

ST CATHERINE’S HOSPICE Primary thromboprophylaxis in advanced disease MJ Johnson.

Warfarin Efficacy in Cancer Patients on Long-term Anticoagulation Neha Doshi, PharmD Candidate LeAnn B. Norris, PharmD, BCPS P. Brandon Bookstaver, PharmD,

Surgical Care Improvement Project Prevention of Post-operative Venous Thromboembolism Team Membership Department of Surgery, Nursing, General Medicine,

Use of Oncotype Dx® Testing Breast SSG meeting 10 th July 2015 Dr Rebecca Bowen.

Confidential: Quality Improvement Material Reducing Clotting Events for Post-Surgical Orthopedic Patients Loyola Anticoagulation Clinic Spring 2009.

SORVEGLIANZA DELLE MALATTIE NEOPLASTICHE. Cancer statistics, 2013 CA: A Cancer Journal for Clinicians Volume 63, Issue 1, pages 11-30, 17 JAN 2013 DOI:

Antithrombotic Therapy for VTE: CHEST Guidelines 2016

Conclusions Results Methods Background Venous thrombo-embolism in patients undergoing neo- adjuvant chemotherapy and surgery for oesophago-gastric cancer.

Venous Thromboembolism & Cancer Dr. Rasna Gupta

Chapter 9: Vascular Complications of Cancer and Cancer Treatment

Taylor Butler, PharmD, BCOP Decentralized Clinical Pharmacist

Extended Treatment of VTE in Cancer Patients

Timeline of Anticoagulation Options

Overall Goal. Clinical Conversations: Nursing Care for Patients With Multiple Myeloma.

Postoperative Calf Venous Thrombosis: Location, Location, Location

Assessment of the Effect of Target Specific Oral Anticoagulants for Treatment of Venous Thromboembolism in Oncology Patients Good morning. My name is.

Thrombosis, Kidney disease & Cancer

UNDERSTANDING YOUR RISK FOR DEVELOPING BLOOD CLOTS (VTE) IN CANCER

D-dimer and helical CT-PA based diagnostic algorithm for PE

Anticoagulants in the Treatment of Venous Thromboembolism

UNDERSTANDING YOUR RISK FOR DEVELOPING BLOOD CLOTS (VTE) IN CANCER

Incidence of postoperative venous thromboembolism in gynecologic surgery by mode of incision Elisa Jorgensen, MD Hye-Chun Hur, MD, MPH Beth Israel.

The heart and science of medicine.

NOACs for Cancer-Associated Thrombosis:

Extended Treatment of VTE: Who is the Right Candidate?

Recurrent venous thromboembolism and bleeding complications during anticoagulant treatment in patients with cancer and venous thrombosis by Paolo Prandoni,

Thrombosis, Cancer, and NOACs

Venous Thromboembolism AND Cancer: Prediction and prevention

Predicting recurrence after unprovoked venous thromboembolism: prospective validation of the updated Vienna Prediction Model by Tobias Tritschler, Marie.

The publication gap in years for the cumulative percent of cited research papers in the ESMO and the UK overall cancer clinical guidelines, with the difference.

The Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) flow chart summarising the process for the identification of eligible studies.

Symptomatic and Incidental Venous Thromboembolic Disease Are Both Associated With Mortality In Patients With Prostate Cancer by Shruti Chaturvedi, Surbhi.

Nat. Rev. Clin. Oncol. doi: /nrclinonc

Prevention and Management of Venous Thromboembolic Events in Patients With Multiple Myeloma.

A Better Solution For Cancer Patients With VTE?

Forest plot of the HRs for DOACs vs warfarin for (A) new or recurrent VTE and (B) major bleeding based on the published subanalyses of the patients with.

Antithrombotic Therapy for VTE Disease

Venous Thromboembolism and Antithrombotic Therapy in Pregnancy

Cancer-Associated Thrombosis

Cost-effectiveness of guidelines for insertion of inferior vena cava filters in high-risk trauma patients Emily L. Spangler, MD, Ellen D. Dillavou, MD,

References: What is the connection between VTE and active cancer? 1. Khorana AA, Francis CW, Culakova E et al. Thromboembolism.

References: Oncological Surgyery: 1. ASCO: Lyman GH, Bohlke K, Khorana AA, et al. Venous Thromboembolism Prophylaxis and Treatment.

How I treat cancer-associated venous thromboembolism

Program Goals Background: Anticoagulation in Patients With VTE.

Patients represented by 441 physicians surveyed from 19 countries, depicted in the patient journey from diagnosis to ensuing treatment with ADT. ADT, androgen.

Treatment and secondary prevention strategy diagram for VTE in patients with active cancer based on the treatment guidelines for cancer-associated VTE.

Incidence of (A) recurrent VTE and (B) major bleeding in select randomised clinical trials of LMWH for the treatment and secondary prevention of VTE in.

Nat. Rev. Gastroenterol. Hepatol. doi: /nrgastro

Awareness of respondents about the availability or development of specialised services for AYA where adult and paediatric cancer specialists work together.

New Concepts in Cancer-Associated Thrombosis

Gender representation of board members in all international societies (reference year: 2016). Gender representation of board members in all international.

Gender representation in all international congresses (reference year 2016). Gender representation in all international congresses (reference year 2016).

Proportion of continuous, intermittent, and limited (

Prevention and Management of Venous Thromboembolic Events in Patients With Multiple Myeloma.

Kaplan-Meier curves for PFS (panel A) and OS (panel B) of patients with mTCC receiving an anti-EGFR based therapy. mTCC, metastatic transverse colon cancer;

A Novel Risk Assessment Model to Predict Venous Thromboembolism (VTE) in Cancer Inpatients: The Canclot Score by Dana E. Angelini, M. Todd Greene, Julie.

Kaplan–Meier analysis of PFS and OS in patients with advanced non-small cell lung cancer with adenocarcinoma histology with time since start of first-line.

Cumulative prevalence of venous thromboembolic events in ITP patients who underwent splenectomy compared with those who did not. Cumulative prevalence.

Kaplan-Meier (K-M) curves of progression-free survival (PFS) in 54 patients with metastatic gastric cancer treated with RAD001. Kaplan-Meier (K-M) curves.

Presentation transcript:

References: Anticoagulation should be continued 3-6 months for the treatment of VTE in cancer patients: 1. ASCO: Lyman GH, Bohlke K, Khorana AA, et al. Venous Thromboembolism Prophylaxis and Treatment in Patients with Cancer: American Society of Clinical Oncology Clinical Practice Guideline Update 2014. J Clin Oncol 2015; 33(6): 654-6. 2. ESMO: Mandalà M, Falanga A, Roila F. Management of Venous Thromboembolism (VTE) in Cancer Patients: ESMO Clinical Practice Guidelines. Ann Oncol 2011; 22 (Suppl 6): vi85-vi92. 3. NCCN: Streiff MB, Holmstrom B, Bockenstedt PL, et al. NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines™). Cancer-Associated Venous Thromboembolic Disease, Version 1, 2017. 4. ISTH: Farge D, Debourdeau P, Beckers M, et al. International clinical practice guidelines for the treatment and prophylaxis of venous thromboembolism in patients with cancer. Journal of Thrombosis and Haemostasis. 2013 Jan 1;11(1):56-70. 5. ACCP: Kearon C, Akl EA, Ornelas J, et al. Antithrombotic Therapy for VTE Disease: CHEST Guideline and Expert Panel Report. Chest 2016; 149(2): 315-52.